Wasatch Advisors Inc. lessened its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 35.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,540 shares of the medical research company’s stock after selling 12,508 shares during the quarter. Wasatch Advisors Inc.’s holdings in Amgen were worth $3,920,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the business. Baker Ellis Asset Management LLC bought a new stake in Amgen during the third quarter worth approximately $108,000. Phocas Financial Corp. bought a new stake in Amgen during the second quarter worth approximately $110,000. Jackson Grant Investment Advisers Inc. boosted its position in Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the period. Omnia Family Wealth LLC boosted its position in Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares during the period. Finally, Horan Capital Advisors LLC. bought a new stake in Amgen during the third quarter worth approximately $150,000. 78.03% of the stock is currently owned by institutional investors.
Amgen, Inc. (NASDAQ:AMGN) opened at $183.55 on Tuesday. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. The company has a market capitalization of $132,259.19, a price-to-earnings ratio of 71.42, a P/E/G ratio of 2.19 and a beta of 1.42. Amgen, Inc. has a 12 month low of $152.16 and a 12 month high of $201.23.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. During the same quarter in the prior year, the company earned $2.89 earnings per share. The business’s revenue was down 2.7% compared to the same quarter last year. research analysts predict that Amgen, Inc. will post 13.21 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a yield of 2.88%. The ex-dividend date is Wednesday, February 14th. Amgen’s dividend payout ratio is currently 205.45%.
Amgen announced that its Board of Directors has approved a stock repurchase program on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
A number of equities research analysts have issued reports on the company. Leerink Swann reaffirmed a “market perform” rating on shares of Amgen in a research report on Friday, February 2nd. Atlantic Securities cut Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 target price for the company. in a research report on Monday, February 5th. Royal Bank of Canada decreased their target price on Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research report on Thursday, October 26th. Oppenheimer set a $205.00 target price on Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Sixteen research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $191.84.
In other news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 4,575 shares of company stock valued at $818,361 over the last quarter. Corporate insiders own 0.19% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Amgen, Inc. (AMGN) Shares Sold by Wasatch Advisors Inc.” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://ledgergazette.com/2018/02/20/amgen-inc-amgn-shares-sold-by-wasatch-advisors-inc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.